These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30808934)

  • 1. Management of cardiovascular risk in patients with multiple myeloma.
    Plummer C; Driessen C; Szabo Z; Mateos MV
    Blood Cancer J; 2019 Feb; 9(3):26. PubMed ID: 30808934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
    Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M;
    Haematologica; 2018 Sep; 103(9):1422-1432. PubMed ID: 30049825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helping the cardio-oncologist: from real life to guidelines.
    Armenian SH; Jurczak W; Carver JR; Gennari A; Minotti G; Ewer MS
    Semin Oncol; 2019 Dec; 46(6):433-436. PubMed ID: 31784041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular complications of multiple myeloma in the elderly.
    Mathur P; Thanendrarajan S; Paydak H; Vallurupalli S; Jambhekar K; Bhatti S; Schinke CD; Davies FE; Mehta JL
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):933-943. PubMed ID: 29164945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
    Cavenagh JD; Popat R
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):501-507. PubMed ID: 29804873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardio-oncological management of patients.
    Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
    Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging options for combination therapy in multiple myeloma.
    Rossi AC
    Clin Adv Hematol Oncol; 2018 Mar; 16(3):192-194. PubMed ID: 29742074
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances.
    Camilli M; La Vecchia G; Lillo R; Iannaccone G; Lamendola P; Montone RA; Hohaus S; Aspromonte N; Massetti M; Lanza GA; Crea F; Graziani F; Lombardo A
    Expert Rev Hematol; 2021 Dec; 14(12):1115-1128. PubMed ID: 34739762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety issues and management of toxicities associated with new treatments for multiple myeloma.
    Brioli A; Mügge LO; Hochhaus A; Von Lilienfeld-Toal M
    Expert Rev Hematol; 2017 Mar; 10(3):193-205. PubMed ID: 28116920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
    Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
    Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in the management of multiple myeloma.
    Kumar L; Verma R; Radhakrishnan VR
    Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.
    Marneni N; Chakraborty R
    Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology
    Breccia M; Carver JR; Szmit S; Jurczak W; Salvatorelli E; Minotti G
    Semin Oncol; 2019 Dec; 46(6):403-407. PubMed ID: 31748121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What a cardiologist needs to know about managing a patient with multiple myeloma].
    Gilles F
    Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):309-316. PubMed ID: 35963791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
    Romano A; Santoro M; Conticello C; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):13-20. PubMed ID: 32955184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
    Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
    Swan D; Routledge D; Harrison S
    Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple myeloma : What has been confirmed in therapy?].
    Baertsch MA; Goldschmidt H
    Internist (Berl); 2017 Dec; 58(12):1250-1257. PubMed ID: 29098319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in a Patient with Concomitant Porphyria Cutanea Tarda.
    Mohamed ZA; Pelletier S; Vintze-Geoffrion A; Lagacé-Nadon S; Olney HJ; Adam JP
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e264-e266. PubMed ID: 33390349
    [No Abstract]   [Full Text] [Related]  

  • 20. How to Think About Risk in Myeloma.
    Krishnan A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S135-8. PubMed ID: 27521310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.